NCT00442455View on ClinicalTrials.gov

Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck

PHASE3CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

Erlotinib chlorhydrate

150 mg/day for 7 weeks

DRUG

Cisplatin

30 mg/m2 i.v. weekly for 7 weeks

PROCEDURE

Radiation therapy

63 Gy, five days a week, for 7 weeks

Trial Locations (5)

28003

Hospital Clínico San Carlos, Madrid

28007

Hospital General Universitario Gregorio Marañón, Madrid

28035

Hospital Universitario Clínica Puerta de Hierro, Madrid

29010

Hospital Regional Universitario Carlos Haya, Málaga

31008

Hospital de Navarra, Pamplona

All Listed Sponsors
lead

Grupo de Investigación Clínica en Oncología Radioterapia

OTHER

NCT00442455 - Erlotinib,Radiation and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter